Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2157-9024
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma ; volume:7 ; number:9 ; day:20 ; month:9 ; year:2018 ; pages:1-11 ; date:9.2018
Oncogenesis ; 7, Heft 9 (20.9.2018), 1-11, 9.2018
- Urheber
-
Irvine, Mal
- Beteiligte Personen und Organisationen
-
Stewart, Ashleigh
Pedersen, Bernadette
Boyd, Suzanah
Kefford, Richard
Rizos, Helen
SpringerLink (Online service)
- DOI
-
10.1038/s41389-018-0081-3
- URN
-
urn:nbn:de:101:1-2018110500185848111161
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:04 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Irvine, Mal
- Stewart, Ashleigh
- Pedersen, Bernadette
- Boyd, Suzanah
- Kefford, Richard
- Rizos, Helen
- SpringerLink (Online service)
Ähnliche Objekte (12)
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
Apoptoseinduktion durch BRAF, MEK Inhibition in humanen Melanomzellen
PI3K-Akt and Raf-MEK-ERK signalling in adipocytes
Zielgerichtete Kombinationstherapie von BRAF- und MEK-Inhibitor resistenten Melanomzellen
MEK + CDK4 a regimen for non-BRAF V6000 melanoma
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report
Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells
RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
ERK5 is activated by oncogenic BRAF and promotes melanoma growth
Oncogenic BRAF induces whole-genome doubling through suppression of cytokinesis
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
Apoptoseinduktion durch BRAF, MEK Inhibition in humanen Melanomzellen
PI3K-Akt and Raf-MEK-ERK signalling in adipocytes
Zielgerichtete Kombinationstherapie von BRAF- und MEK-Inhibitor resistenten Melanomzellen
MEK + CDK4 a regimen for non-BRAF V6000 melanoma
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report
Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells
RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
ERK5 is activated by oncogenic BRAF and promotes melanoma growth
Oncogenic BRAF induces whole-genome doubling through suppression of cytokinesis
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
Apoptoseinduktion durch BRAF, MEK Inhibition in humanen Melanomzellen
PI3K-Akt and Raf-MEK-ERK signalling in adipocytes
Zielgerichtete Kombinationstherapie von BRAF- und MEK-Inhibitor resistenten Melanomzellen
MEK + CDK4 a regimen for non-BRAF V6000 melanoma
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report
Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells
RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
ERK5 is activated by oncogenic BRAF and promotes melanoma growth